Global Myocardial Infarction Drugs Market - 2020-2027
発行: DataM Intelligence
The global myocardial infarction Drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occurs to individuals with risk factors such as diabetes and dyslipidemia.
The global myocardial infarction drugs market growth is driven by the growth in incidences of cardiovascular diseases as well as hypertension, diabetes, and obesity.
Increasing incidence of coronary artery disease and changes in lifestyle
Increasing incidence of coronary artery disease and changes in lifestyle are the major factors expected to drive the growth of global myocardial infarction therapeutics market. Increasing number of smokers, increasing incidence of obesity and blood pressures, lack of exercise can be some other reasons likely to flourish the global myocardial infarction therapeutics market over the forecast period. WHO data show that the death rate due to cardiovascular diseases is more in smokers than that in non-smokers.
Moreover, according to the Heart Foundation, by the end of 2014, approximately 920,000 people in the U.S. will have a heart attack. Thus, this large base of heart patients is expected to drive the market growth of the market in the forecast period.
High incidence rate of obesity along with chronic diseases will drive market
High incidence rate of obesity along with chronic diseases such as diabetes, hypertension and chronic kidney diseases are also driving the market growth. They are also embarking upon partnerships with retail chain companies to improve sales. urthermore, unhealthy lifestyle practices, excessive alcohol consumption and use of drugs such as amphetamines and cocaine, among population are the important risk factors for myocardial infarction, alternatively, which would boosts the growth of myocardial infarction drugs market in the near future. expected technological breakthroughs will generate abundant opportunities for detecting targeted blockages, monitoring cellular response and for determining genetic predisposition, which might alternatively drive the growth of the market.
Stringent regulatory policies and high costs of clinical trials is likely to hinder the market growth
On the contrary, rise in overall healthcare expenditure, stringent regulatory policies and high costs of clinical trials are some of the market-restraining factors that will hamper the growth of myocardial infarction drugs market in the forecast period.
COVID-19 Impact Analysis
Contrary to the anticipated surge in myocardial infarction (MI) related to the novel coronavirus, there have been reports that the COVID-19 pandemic has significantly reduced the number of activations for ST-elevation myocardial infarction (STEMI) in a majority of cities with devastating spread of COVID-19 cases. Thus, the pandemic has incresed the sale of drugs and ultimately growth of the myocardial infarction drugs market in the forecast period.
Market Segment Analysis
By product type, the myocardial infarction drugs market is classified into analgesics, antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ace) inhibitors, and others.
Analgesics segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Analgesics are also known as pain killer which is used to treat various different types of pain such as wounds, surgeries and others. There are various opioids and non-opioids and combination drugs are there which are used in the pain management. These drugs are generally used for unbearable pain and pain management. Pain management is a major domain for chronic disorders such as cancer, cardiovascular and others. For instance, according to American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death. In 2012, British Heart Foundation reported 73,680 deaths in United Kingdom due to coronary heart disease. Mortality from acute myocardial infarction can be decreased if patient receives the emergency access to the treatment.
In addition, the increasing therapeutic benefits offered by analgesics, in addition to effective and fast relief from pain, have significantly driven the demand for analgesics over the years. The development of innovative drugs and rising awareness about these treatment options have also supported the analgesics segment.
Morphine sulfate : Morphine sulfate is an opioid agonist indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate occurs as white, feathery, silky crystals; cubical masses of crystal; or white crystalline powder. It is soluble in water and slightly soluble in alcohol, but is practically insoluble in chloroform or ether. In addition to analgesia, the widely diverse effects of morphine sulfate include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous system.
Antiplatelet agents segment will also have the positive growth in the forecast period. An antithrombotic agent is a drug that reduces the formation of blood clots. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot. Antithrombotic is a drug that helps reduce thrombus formation. Different antithrombotic affect different blood clotting processes like antiplatelet drugs, anticoagulants, and thrombolytic drugs. Its main application is to treat the abnormal blood flow in the human body. The major causes of thrombosis are inactivity, blood vessel damage, medical and genetic conditions, pregnancy, obesity. With the growing population across the globe, the demand for such life savings drugs is bound to increase. An antiplatelet drug is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
For instance, according to the data provided by the American Heart Association, there are about 800,000 individuals suffer from stroke every year in the U.S. among these three out of four-experience stroke the very first time. Of these, 87% are ischemic strokes. Moreover, based on the data provided by the Centers for Disease Control and Prevention, 735,000 people have a heart attack in Latin America and North America. Of these 525,000 people experience heart attack the very first time. Thus, the growing trend of these diseases has led to the growth of the antiplatelet drugs.
Aspirin : Aspirin, also called acetylsalicylic acid, derivative of salicylic acid that is a mild nonnarcotic analgesic (pain reliever) useful in the relief of headache and muscle and joint aches. Aspirin is effective in reducing fever, inflammation, and swelling and thus has been used for treatment of rheumatoid arthritis, rheumatic fever, and mild infection. In these instances, aspirin generally acts on the symptoms of disease and does not modify or shorten the duration of a disease. However, because of its ability to inhibit the production of blood platelet aggregates (which may cut off the blood supply to regions of the heart or brain), aspirin has also been used as an anticoagulant in the treatment of conditions such as unstable angina or following a minor stroke or heart attack.
Vorapaxar : Vorapaxar is used to lower the risk of stroke or serious heart problems in people who have had a heart attack or a blood vessel disorder affecting circulation in the arms and legs.
It is found on platelets and is activated by thrombin resulting in platelet aggregation and formation of a vascular clot. The aggregation of platelets also plays an important role in the growth of atheromatous plaques, which can lead to coronary, cerebral and peripheral arterial occlusions.
Market Geographical Analysis
North America region holds the largest market share global Myocardial Infarction Drugs market
North America region is dominating the global myocardial infarction drugs market accounted for the largest market share in 2019, due to high incidence and prevalence rate of cardiac diseases coupled with increasing base of obese population. According to the Centers for Disease Control and Prevention (CDC), approximately 600,000 people in the U.S. die of heart disease annually. The organization also claims that annually the U.S. spends around USD 108.9 billion on treatment and management of coronary heart diseases. Moreover, according to the Heart Foundation, by the end of 2014, approximately 920,000 people in the U.S. will have a heart attack. Thus, this large base of heart patients is expected to drive the market growth of myocardial infarction treatment in this region.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period. Owing to the high incidence rate of heart diseases and high adoption rate for advanced therapeutics, these regions are expected to be the potential market in the near future.
Market Competitive Landscape
The Myocardial Infarction Drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bayer HealthCare LLC, Daiichi Sankyo, Inc., Eli Lilly and Company, Janssen Biotech, Inc., Merck & Co. Inc., Novartis International AG and Sanofi amongst, Cadila Pharmaceuticals others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myocardial infarction drugs market globally.
Overview: Cadila Pharmaceuticals Ltd. is privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company's formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved.
Product Portfolio: The Company's portfolio comprised of cardiovascular, gastrointestinal, analgesics, hematinic, anti-invectives' and antibiotics, respiratory agents, antidiabetics and immunological.
Key Development: In October 2020, Cadila Pharmaceuticals launches Tikacad in India, an anti-platelet drug-containing Ticagrelor, a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
The global myocardial infarction drugs market report would provide an access to an approx. 52 market data table, 48 figures and 250 pages.
LIST NOT EXHAUSTIVE